Please assess the completion status of the following clinical trial:

Trial Title: Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has provided written informed consent~* Has adenocarcinoma of the colon or rectum~* Has failed at least 2 prior regimens of standard chemotherapies for metastatic colorectal cancer~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Is able to take medication orally~* Has adequate organ function (bone marrow, kidney and liver)~* Women of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS-102 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).